Effects of Sacubitril/Valsartan on clinical symptoms, echocardiographic parameters, and outcomes in HFrEF and HFmrEF patients with coronary heart disease and chronic kidney disease

CONCLUSION: Sacubitril/valsartan significantly improved morphofunctional remodeling parameters and clinical symptoms in HFrEF patients than in HFmrEF patients.PMID:33764230 | DOI:10.1080/03007995.2021.1908243

Source: Current Medical Research and Opinion - March 25, 2021 Category: Research Authors: Dominick Mkombozi Raphael Zhiyu Liu Zhi Jin Xinyue Cui Dongjian Han Weiwei He Jiahong Shangguan Deliang Shen Source Type: research